';
Authors Posts by Cathy Barrick

Cathy Barrick

332 POSTS 0 COMMENTS

The Pennsylvania Department of Labor and Industry (L&I), Office of Vocational Rehabilitation (OVR), is looking for a partner to deliver and manage their InVEST Project services in the eastern region of Pennsylvania. The federally funded InVEST Project (Grant # H421D220003) will assist individuals with disabilities in finding fulfilling jobs in their communities while meeting the unique workforce needs of green and transportation-related industries.

If you’re interested in applying, visit PA eMarketplace.

The Office of Developmental Programs (ODP) has shared the attached communication, ODPANN 24-017: Open for Public Comment: Proposed Waiver Amendments for One-Time Workforce Recovery Supplemental Payments. The purpose of this communication is to announce that proposed amendments to the Consolidated, Person/Family Directed Support (P/FDS), Community Living, and Adult Autism Waivers are available for public review and comment. There is a 30-day public comment period that starts on February 3, 2024, and ends on March 4, 2024, at 11:59 pm.

Comments: Interested persons are invited to submit written comments regarding the proposed waiver amendments as outlined below. Comments received by 11:59 pm on March 4, 2024, will be reviewed and considered for revisions to the waiver amendments submitted to the Centers for Medicare and Medicaid Services (CMS).

Comments and requests for copies of this notice and documents should be addressed to: Julie Mochon Department of Human Services, Office of Developmental Programs, 625 Forster Street, Room 510, Harrisburg, PA 17120.

Comments and requests for copies of this notice and documents may also be submitted to ODP via email. Comments submitted should use subject header ”Waiver Comments.”

Contact: Questions about this communication should be directed to this email address.

A Request for Proposals (Solicitation/Project#:6100060351) for a single contract in the eastern region of Pennsylvania with the Office of Vocational Rehabilitation (OVR) for the PA SWTCIE Grant’s InVEST Project has been issued. Interested parties should access information regarding this opportunity on the PA eMarketplace website.

The InVEST Project is seeking to increase competitive integrated employment outcomes for individuals who are engaged, or are considering engagement, in subminimum wage employment. The project is funded through the Disability Innovation Fund (DIF) Subminimum Wage to Competitive Integrated Employment Grant, a federal model demonstration grant from the Rehabilitation Services Administration (PR Award # H421D220003).

The Office of Developmental Programs (ODP) has shared ODPANN 24-015.The purpose of this communication is to provide guidance for implementing changes to assistive technology and remote supports in the amendments to the Consolidated, Community Living, Person/Family Directed Support (P/FDS) and Adult Autism Waivers. View the announcement and the forms below for details.

The Office of Developmental Programs (ODP) has shared ODPANN 24-014. The purpose of this announcement is to communicate that Temple University Harrisburg Certified Investigator Program and ODP will be facilitating Forums for Certified Investigators (CI) and others involved in the incident investigation process. This also announces the posting of Q&A documents from past CI Forums on myODP. Please view the announcement for information and details.

The Office of Developmental Programs (ODP) has shared this important announcement from the U.S. Food and Drug Administration (FDA) about a recall of two cough medicine products by Robitussin. The products are Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult. Please see the specific Lot Numbers below that are involved in the recall.  If you have one of these products with the matching Lot Number, stop use immediately and contact your health care provider.


Haleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult Products Due to Microbial Contamination

Summary
Company Announcement Date: January 24, 2024
FDA Publish Date: January 24, 2024
Product Type: Drugs
Reason for Announcement: Microbial Contamination
Company Name: Haleon
Brand Name: Robitussin
Product Description: Cough syrups

Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination.

In immunocompromised individuals, the use of the affected product could potentially result in severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur. However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out. To date, Haleon has not received any reports of adverse events related to this recall.

Robitussin Honey CF Max Day and Nighttime are cough syrups indicated for the temporary relief of symptoms occurring with cold or flu, hay fever, or other respiratory allergies. This recall covers only the following lots:

Product Lot Number Expiry Date
ROBITUSSIN HONEY CF MAX
DAY ADULT 4OZ
T10810 31OCT2025
ROBITUSSIN HONEY CF MAX
DAY ADULT 8OZ
T08730
T08731
T08732
T08733
T10808
31MAY2025
31MAY2025
31MAY2025
31MAY2025
30SEP2025
ROBITUSSIN HONEY CF MAX
NT ADULT 8OZ
T08740 T08742 30JUN2026
30JUN2026

Haleon is notifying its distributors and customers directly and has provided them with instructions for the return of all recalled products. Consumers that have purchased the product listed should stop consumption immediately. Please call our Consumer Relations team at +1-800-245-1040 (Monday through Friday 8:00 am – 6:00 pm Eastern Time) or reach out via email.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

  • Complete and submit the report online
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

The Office of Developmental Programs (ODP) has released ODPANN 24-013. This announcement shares details regarding the registration for six half-day virtual training sessions focused on ODP’s expectations of Residential Provider Program Specialists in the implementation of the Residential ISP Staffing approach. Please view the announcement for information and details.

February continues the series on Participant Directed Services. Creating an Everyday Life using Waiver Services comes with some exciting opportunities and challenges. Many individuals use Participant Directed Services to pursue their vision and create the life they want. Please join the PA Family Network (PAFN) as they explore more about Participant Direction and offer resources and information. These workshops are created by family members and self-advocates FOR family members and self-advocates.

Register here for upcoming events.

Support Groups

LifeCourse Workshops

Waiver Workshops

  • Waiver Advanced, Part 1: Monday, February 5, 2024
  • Waiver Advanced, Part 2: Monday, February 12, 2024
  • Waiver Basics, Part 1: Thursday, February 22, 2024

Community Engagement Workshops:
There will be an afternoon and evening session each day.

Join us for our Participation Direction Summits this spring!

Visit the PA Family Network website for more information about our summit sessions, lunch, and dinner!